vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and IMAX CORP (IMAX). Click either name above to swap in a different company.
Azenta, Inc. is the larger business by last-quarter revenue ($148.6M vs $125.2M, roughly 1.2× IMAX CORP). IMAX CORP runs the higher net margin — 0.5% vs -10.4%, a 10.9% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 0.8%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $14.7M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 4.4%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
AZTA vs IMAX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $125.2M |
| Net Profit | $-15.4M | $637.0K |
| Gross Margin | 42.9% | 57.6% |
| Operating Margin | -4.9% | 19.3% |
| Net Margin | -10.4% | 0.5% |
| Revenue YoY | 0.8% | 35.1% |
| Net Profit YoY | -15.7% | -88.0% |
| EPS (diluted) | $-0.34 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.6M | $125.2M | ||
| Q3 25 | $159.2M | $106.7M | ||
| Q2 25 | $143.9M | $91.7M | ||
| Q1 25 | $143.3M | $86.7M | ||
| Q4 24 | $147.4M | $92.7M | ||
| Q3 24 | $150.6M | $91.5M | ||
| Q2 24 | $144.3M | $89.0M | ||
| Q1 24 | $136.4M | $79.1M |
| Q4 25 | $-15.4M | $637.0K | ||
| Q3 25 | $50.9M | $20.7M | ||
| Q2 25 | $-48.0M | $11.3M | ||
| Q1 25 | $-47.7M | $2.3M | ||
| Q4 24 | $-11.0M | $5.3M | ||
| Q3 24 | $-6.6M | $13.9M | ||
| Q2 24 | $-6.6M | $3.6M | ||
| Q1 24 | $-137.4M | $3.3M |
| Q4 25 | 42.9% | 57.6% | ||
| Q3 25 | 45.4% | 63.1% | ||
| Q2 25 | 46.2% | 58.5% | ||
| Q1 25 | 43.8% | 61.4% | ||
| Q4 24 | 46.7% | 52.2% | ||
| Q3 24 | 45.5% | 55.8% | ||
| Q2 24 | 44.8% | 49.4% | ||
| Q1 24 | 43.8% | 59.3% |
| Q4 25 | -4.9% | 19.3% | ||
| Q3 25 | 1.2% | 27.2% | ||
| Q2 25 | -1.3% | 15.6% | ||
| Q1 25 | -12.7% | 19.3% | ||
| Q4 24 | -5.9% | 10.3% | ||
| Q3 24 | -3.1% | 21.2% | ||
| Q2 24 | -4.9% | 3.2% | ||
| Q1 24 | -18.1% | 15.3% |
| Q4 25 | -10.4% | 0.5% | ||
| Q3 25 | 32.0% | 19.4% | ||
| Q2 25 | -33.4% | 12.3% | ||
| Q1 25 | -33.3% | 2.7% | ||
| Q4 24 | -7.5% | 5.7% | ||
| Q3 24 | -4.4% | 15.2% | ||
| Q2 24 | -4.5% | 4.0% | ||
| Q1 24 | -100.8% | 4.1% |
| Q4 25 | $-0.34 | $0.02 | ||
| Q3 25 | $1.12 | $0.37 | ||
| Q2 25 | $-1.05 | $0.20 | ||
| Q1 25 | $-1.04 | $0.04 | ||
| Q4 24 | $-0.25 | $0.09 | ||
| Q3 24 | $-0.25 | $0.26 | ||
| Q2 24 | $-0.12 | $0.07 | ||
| Q1 24 | $-2.48 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $151.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.7B | $337.9M |
| Total Assets | $2.1B | $894.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $336.6M | $151.2M | ||
| Q3 25 | $279.8M | $143.1M | ||
| Q2 25 | $270.0M | $109.3M | ||
| Q1 25 | $253.6M | $97.1M | ||
| Q4 24 | $377.5M | $100.6M | ||
| Q3 24 | $280.0M | $104.5M | ||
| Q2 24 | $336.5M | $91.6M | ||
| Q1 24 | $353.5M | $81.0M |
| Q4 25 | $1.7B | $337.9M | ||
| Q3 25 | $1.7B | $349.5M | ||
| Q2 25 | $1.7B | $320.4M | ||
| Q1 25 | $1.7B | $299.5M | ||
| Q4 24 | $1.7B | $299.5M | ||
| Q3 24 | $1.8B | $289.4M | ||
| Q2 24 | $2.0B | $267.2M | ||
| Q1 24 | $2.2B | $258.8M |
| Q4 25 | $2.1B | $894.0M | ||
| Q3 25 | $2.1B | $889.6M | ||
| Q2 25 | $2.0B | $868.6M | ||
| Q1 25 | $2.0B | $848.3M | ||
| Q4 24 | $2.0B | $830.4M | ||
| Q3 24 | $2.1B | $847.6M | ||
| Q2 24 | $2.3B | $827.4M | ||
| Q1 24 | $2.6B | $824.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $29.4M |
| Free Cash FlowOCF − Capex | $14.7M | $28.0M |
| FCF MarginFCF / Revenue | 9.9% | 22.3% |
| Capex IntensityCapex / Revenue | 4.2% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.8M | $29.4M | ||
| Q3 25 | $2.2M | $67.5M | ||
| Q2 25 | $25.8M | $23.2M | ||
| Q1 25 | $14.4M | $7.0M | ||
| Q4 24 | $29.8M | $11.5M | ||
| Q3 24 | $17.7M | $35.3M | ||
| Q2 24 | $9.8M | $35.0M | ||
| Q1 24 | $8.7M | $-11.0M |
| Q4 25 | $14.7M | $28.0M | ||
| Q3 25 | $-5.7M | $64.8M | ||
| Q2 25 | $15.0M | $20.9M | ||
| Q1 25 | $7.0M | $5.3M | ||
| Q4 24 | $22.0M | $6.9M | ||
| Q3 24 | $8.3M | $34.2M | ||
| Q2 24 | $1.3M | $33.5M | ||
| Q1 24 | $428.0K | $-12.1M |
| Q4 25 | 9.9% | 22.3% | ||
| Q3 25 | -3.6% | 60.7% | ||
| Q2 25 | 10.4% | 22.8% | ||
| Q1 25 | 4.9% | 6.1% | ||
| Q4 24 | 15.0% | 7.4% | ||
| Q3 24 | 5.5% | 37.3% | ||
| Q2 24 | 0.9% | 37.6% | ||
| Q1 24 | 0.3% | -15.3% |
| Q4 25 | 4.2% | 1.1% | ||
| Q3 25 | 4.9% | 2.6% | ||
| Q2 25 | 7.5% | 2.6% | ||
| Q1 25 | 5.2% | 1.9% | ||
| Q4 24 | 5.3% | 5.0% | ||
| Q3 24 | 6.2% | 1.2% | ||
| Q2 24 | 5.9% | 1.8% | ||
| Q1 24 | 6.1% | 1.4% |
| Q4 25 | — | 46.11× | ||
| Q3 25 | 0.04× | 3.27× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 2.54× | ||
| Q2 24 | — | 9.78× | ||
| Q1 24 | — | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
